BioTech Pharma Summit: Companion Diagnostics & Biomarkers

Predictive Biomarkers and Companion Diagnostics to Guide Cancer Immunotherapy

Robert Hawkins

June 16, 2017

Robert Hawkins is Cancer Research UK Professor at the University of Manchester and Christie Hospital. His research interests are in gene and immunotherapy of cancer. In addition to clinical training at the Royal Marsden Hospital and Addenbrookes Hospital in Cambridge he was an MRC Research Fellow with Dr Greg Winter and Dr Cesar Milstein at the MRC laboratory of Molecular Biology in Cambridge. His PhD was in antibody engineering and as a Cancer Research UK Senior Clinical Fellow he developed translational research interests in antibody based gene therapy. He was first appointed as a consultant in Medical Oncology at Addenbrooke’s Hospital in Cambridge in 1995 and then became Professor of Oncology at the University of Bristol in 1996. In 1998 he moved to the Christie Hospital to become Professor and Director of Medical Oncology. Clinically, Professor Hawkins focuses on treating renal cancer and cancer of the oesophagus/stomach. He heads a clinical research group undertaking trials in these cancers and also a range of early phase clinical trials of biological agents including vaccines, antibodies and cellular therapy.

He has co-ordinated major grants from the European Union including the ATTACK projects and was coordinator of the ATTRACT integrated training network. He has published widely in scientific and clinical journals and is an inventor/co-inventor on several antibody related patents. Professor Hawkins also lead the development of a Cellular Therapeutics Unit based at the University of Manchester Incubator Building to faciitate translational research in cell therapy for cancer. This GMP unit has developedi nto a successful biotechnology company developing adoptive cell therapy for cancer. The company also provides expert manufacturing services in other areas of cell therapy